Diane Weiser
Senior Vice President of Corporate Affairs
Replay available
Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call
Cytokinetics, Incorporated (NASDAQ: CYTK) Q2 2025 earnings conference call, held 2025-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Robert Blum
President and Chief Executive Officer
Andrew Kellis
Executive Vice President and Chief Commercial Officer
Betty Malek
Executive Vice President of Research and Development
Stuart Kupfer
Senior Vice President and Chief Medical Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cytokinetics, Incorporated.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:01.473 mode. 00:00:01.473 -- 00:00:05.217 After the speaker's remarks, we will open the call to questions. 00:00:05.217 -- 00:00:08.680 We will allow for one question per participant. 00:00:08.680 -- 00:00:12.304 If you would like to ask a question during this time, simply press the star followed 00:00:12.304 -- 00:00:14.907 by the number one on your telephone keypad. 00:00:14.907 -- 00:00:17.811 If you would like to withdraw your question, please press the star one again. 00:00:17.811 -- 00:00:22.876 I would now like to turn the call over to Diane Weiser, Platykinetics 00:00:22.876 -- 00:00:25.739 Senior Vice President of Corporate Affairs. 00:00:25.739 -- 00:00:28.140 Please go ahead. 00:00:28.280 -- 00:00:31.803 Good afternoon, and thanks for joining us on the call today. 00:00:31.803 -- 00:00:36.227 Robert Blum, President and Chief Executive Officer, will begin with an overview of the 00:00:36.227 -- 00:00:39.230 quarter and recent developments. 00:00:39.230 -- 00:00:44.715 Andrew Kellis, EVP and Chief Commercial Officer, will address commercial readiness activities 00:00:44.715 -- 00:00:49.960 for Affy Campton. Betty Malek, EVP of R&D, will provide updates related to the clinical 00:00:49.960 -- 00:00:54.405 development program and medical affairs activities for Affy Campton. 00:00:54.405 -- 00:00:59.282 Stuart Kupfer, SVP and Chief Medical Officer, will provide updates on the clinical development 00:00:59.282 -- 00:01:05.048 program for Omicamp and CK586, which is now called Eulacamp. 00:01:05.048 -- 00:01:09.792 Emily, EVP and Chief Financial Officer, will provide a financial overview of the past 00:01:09.792 -- 00:01:14.737 quarter. And finally, Robert will provide closing comments and review our expected key 00:01:14.737 -- 00:01...